DropGenie raises $5 million USD backed by BDC to speed up biological discovery

DropGenie raises $5 million USD backed by BDC to speed up biological discovery

Montréal and Boston-based biotech startup aims to draw more data out of small samples. The post DropGenie raises $5 million USD backed by BDC to speed up biological discovery first appeared on BetaKit . Montréal and Boston-based biotech startup aims to draw more data out of small samples. From a single drop of blood, you can find a whole world of biological information. One biotech startup is hoping that its miniaturized technology can make scientific research easier and more efficient, even when very little patient material is available. DropGenie, based in Montréal and Boston, is betting its approach can help the pharmaceutical industry develop more therapies. The company announced on Monday morning that it has brought in BDC Capital’s Thrive Fund as a new investor for its seed-plus financing, bringing the total equity round to $5 million USD ($7 million CAD). Massachusetts-based Skeleton Key had led that financing, alongside Merck Global Health Innovation Fund and CQDM, with participation from Montréal’s Real Ventures and Anges Québec. DropGenie hopes to make personalized medicines possible “by doing the somewhat unsexy work of creating … automation systems.” Alison Hirukawa, DropGenie Founded in 2018, DropGenie began when CEO Alison Hirukawa met her co-founders, who were working on a digital microfluidics platform. The platform used electrical signals to manipulate very sma.